GSP Crop Science Q1 FY27: Margins Improve on Mix, Exports Stay Soft

GSP Crop Science Limited closed Q1 FY27 with stable top line growth and better profitability, even as export dispatches faced timing and raw material related disruptions. On a consolidated basis, revenue from operations came in at INR 3,860 million for the quarter ended June 30, 2026, compared with INR 3,770 million in Q1 FY26. EBITDA was INR 425 million and profit after tax was INR 264 million, up 16.8% year on year.

Management positioned the quarter as a “stable” outcome given volatility in input prices and supply chains. The domestic business showed momentum, while the international business was held back by temporary constraints and customer buying delays. The company also flagged that its business remains Kharif-led, making Q2 the most important quarter for domestic demand.

What moved the numbers in Q1

The most notable operational improvement in the quarter was at the gross margin line. Gross profit rose to INR 1,424 million, with gross margin improving to 36.9% from 34.5% a year ago. Management attributed this primarily to a better product mix. In the earnings call, it linked the mix improvement to a higher share of differentiated and patented products in the branded portfolio, along with healthy contribution from the B2B channel.

At the operating cost level, employee costs increased year on year due to higher headcount and annual increments. Other expenses were also higher versus the prior year quarter, which management linked to commencement of operations at a new subsidiary unit and foreign exchange movements.

Other income increased sharply to INR 83 million from INR 26 million in Q1 FY26. On the call, management clarified that around INR 5.7 crore of this other income related to a one-off gain on sale of lease land, and it does not expect similar other income in upcoming quarters.

Interest costs reduced year on year due to loan repayment using IPO proceeds. Management also highlighted that ICRA upgraded the company’s long-term rating to A+ (stable) and short-term rating to A1, largely on the back of debt repayment and continued performance.

Financial snapshot (consolidated)

Channel mix and where growth is coming from

GSP operates across three channels: domestic B2C branded, domestic B2B, and exports. In Q1 FY27, management shared that the revenue mix was about 45% domestic B2C, 45% domestic B2B, and 10% exports. This skew towards domestic channels in Q1 is consistent with seasonality, since exports, especially to Brazil, tend to pick up in the second half of the Indian financial year.

From a product perspective, management indicated that around 75% of the business is formulations and 25% is technicals. It also shared capacity utilisation trends: technical capacity utilisation is around 70% to 75%, while formulation plants operate at 25% to 30% because they are designed to handle peak seasonal demand and formulation processes can also be outsourced.

A key strategic lever the company keeps returning to is the patented and differentiated portfolio within the branded business. Management said patented products are currently around 20% to 22% of the B2C business, and the company aims to almost double this share over the next three years. In Q1, it credited gross margin improvement partly to this shift.

Exports: H2 dependency and Brazil caution

Exports were the biggest swing factor discussed in Q1. The investor presentation stated that international business revenue was up 20% over last year, supported by planned sales in Brazil, the USA, and Africa. It also highlighted that a new registration in Brazil for Chlorpyriphos received last year helped sales, and that the company has initiated additional registrations across Brazil, Africa, the Middle East and Asian countries, with focus on registrations for Chlorantraniliprole and Methoxyfenzoide.

However, the earnings call commentary was more cautious for the near term. Management described delayed buying patterns in Brazil, where customers held back purchases amid volatile pricing. Because of the delay, delivery timelines became critical, and the company saw some orders shift to China due to China’s logistics advantage, even where GSP was cost competitive.

It also acknowledged liquidity and credit challenges in Brazil. As a result, it is focusing more on established B2B customers for Brazilian business and exploring smaller pockets in Latin America such as Argentina and Uruguay through tie-ups with second-tier distributors.

Strategy recap: patents, backward integration, and deleveraging

The strategic blueprint in the presentation centres on three themes.

First, expand internationally by leveraging R&D and a diverse portfolio and by filing registrations to enter more markets.

Second, expand via R&D innovation. The presentation highlighted an IP portfolio with 112 granted patents and 114 applications under process, and also stated that patented products’ revenue share rose to 20.73% in H1 FY25 from 5.07% in FY22. Management reiterated that it targets off-patent molecules to be among early domestic launchers and also develops proprietary combination products.

Third, backward integration and efficiency. The company is establishing the Saykha facility for backward integration and raw material security to reduce import dependency and improve supply chain control. In the earnings call, management linked the increase in depreciation to capitalisation of the backward integration plant at Dahej, Saykha.

Alongside these growth priorities, deleveraging remains central. The presentation states a debt reduction of INR 2,200 million using IPO proceeds. On the call, management confirmed that it repaid loans as per IPO objectives during the quarter, with a small amount pending closure due to bank settlements for brokerage expenses.

Takeaways for investors

Q1 FY27 reinforced two parts of the GSP story. The first is that domestic execution and mix improvement can lift margins even when revenue growth is modest. The second is that exports, especially Brazil, can remain volatile due to timing, logistics, and customer liquidity.

The key milestones to track over the next few quarters are the performance in Q2 (given the Kharif skew), the pace of patented portfolio scaling within B2C, and whether export demand normalises in H2 as management expects. The company’s ability to convert backward integration into more stable sourcing and to sustain gross margin improvements will likely define the quality of earnings beyond the seasonal peak.